Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy

ABSTRACT: Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy

PROVIDER: PRJNA914986 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22861935_1.fastq.gz	Fastqsanger.gz
	SRR22861935_2.fastq.gz	Fastqsanger.gz
	SRR22861936_1.fastq.gz	Fastqsanger.gz
	SRR22861936_2.fastq.gz	Fastqsanger.gz
	SRR22861937_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 60

Similar Datasets

Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy

Project description:Objectives: Vγ9Vδ2 T-cells are a subset of T-cells with a crucial role in immunosurveillance which can be activated and expanded by multiple means to stimulate effector responses. Little is known about the expression of checkpoint molecules on this cell population and whether the ligation of these molecules can regulate their activity. The aim of this study was to assess the expression of both activatory and inhibitory receptors on Vγ9Vδ2 T-cells to assess potential avenues of regulation to target with immunotherapy. Methods: Expression of various activatory and inhibitory receptors was assessed on Vγ9Vδ2 T-cells by flow cytometry following activation and expansion using zoledronic acid (ZA) and Bacillus Calmette-Guérin (BCG). Expression of these markers and production of effector molecules was also examined following co-culture with various tumour cell targets. The effect of immune checkpoint blockade on Vγ9Vδ2 T-cells was also explored. Results: Vγ9Vδ2 T-cells expressed high levels of activatory markers both at baseline and following stimulation. Vγ9Vδ2 T-cells expressed variable levels of inhibitory checkpoint receptors with many being upregulated following stimulation. Expression of these markers is further modulated upon co- culture with tumour cells with changes reflecting activation and effector functions. Despite their high expression of inhibitory receptors when cultured with tumour cells expressing cognate ligands there was no effect on Vδ2+ T-cell cytotoxic capacity or cytokine production with immune checkpoint blockade. Conclusions: Our work suggests the expression of checkpoint receptors present on Vγ9Vδ2 T-cells which may provide a mechanism with the potential to be utilised by tumour cells to subvert Vγ9Vδ2 T-cell cytotoxicity. This work suggests important candidates for blockade by ICI therapy in order to increase the successful use of Vγ9Vδ2 T-cells in immunotherapy.

2023-01-02 | GSE221563 | GEO

An In Vitro Exhaustion Model for Vγ9Vδ2 T Cells: Characterization and Reactivation Strategies for Advancing Immunotherapy Development

Project description:Recent advancements in cancer immunotherapies have highlighted the potential of Vγ9Vδ2 T cells as key players in the immune response against cancer. These cells, initially recognized for their broad activity in combating infections and tumors, are now emerging as promising candidates for targeted immunotherapeutic strategies, including T cell Engagers (TCEs). However, like other immune cells, Vγ9Vδ2 T cells can enter a state of dysfunction and exhaustion within the tumor microenvironment, driven by factors such as TCR overstimulation, immunosuppressive cytokines (e.g., TGF-β), and hypoxia. While the mechanisms of T cell exhaustion have been extensively studied in in vivo CD8+ T cells, the lack of a murine Vγ9Vδ2 subset complicates the investigation and generation of large numbers of exhausted Vγ9Vδ2 T cells. To address this, we present a novel in vitro protocol for rapidly generating exhausted Vγ9Vδ2 T cells through co-culture with Zoledronate activated human tumor cells. We characterized the resulting cells using phenotypic, metabolomic, and transcriptomic analyses, comparing their profiles to published data on in vivo-exhausted cells. Furthermore, we measured the reactivation potential of these exhausted Vγ9Vδ2 T cells using anti-CD3 monoclonal antibodies, demonstrating that CD3 stimulation can partially reverse exhaustion and restore anti-tumor effector functions. Furthermore, exhausted Vγ9Vδ2 T cells retained some cytotoxic activity upon stimulation with T Cell Engagers, underscoring the versatility and applicability of our in vitro exhaustion model. This model offers a robust platform for the evaluation of novel immunotherapies targeting Vγ9Vδ2 T cells, facilitating preclinical assessments before transitioning to in vivo studies.

2026-07-31 | GSE303586 | GEO

Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy.

Project description: Not available

| S-EPMC9880221 | biostudies-literature

Upregulation of BTN3A1 on CD14+ cells promotes Vγ9Vδ2 T cells activation in psoriasis vulgaris

Project description:Vγ9Vδ2 T cells play an important role in the development and progression of psoriasis vulgaris (PV), but how they promote skin inflammation and the molecular mechanisms underlying Vγ9Vδ2 T cell dysfunction are poorly understood. Here, we show that circulating Vγ9Vδ2 T cells are decreased and exhibit enhanced proliferation and increased production of IFN-γ and TNF-α in PV patients. Monocytes from PV patients express higher levels of the phosphoantigen sensor butyrophilin 3A1 (BTN3A1) than monocytes from healthy controls. Blockade of BTN3A1 suppresses Vγ9Vδ2 T cell activation and abolishes the difference in Vγ9Vδ2 T cell activation between PV patients and healthy controls. The CD14+ cells in PV skin lesions highly express BTN3A1 and juxtapose to Vδ2 T cells. In addition, IFN-γ induces the up-regulation of BTN3A1 on monocytes. Collectively, our results demonstrate a crucial role of BTN3A1 on monocytes in regulating Vγ9Vδ2 T cell activation and highlight BTN3A1 as a potential therapeutic target for psoriasis.

2022-11-09 | GSE173387 | GEO

Expression data from iPSC-derived mimetic Vγ9Vδ2 T cells and mimetic NK cells

Project description:We designed and demonstrated a synthetic strategy to derive mimetic Vγ9Vδ2 T cells endowed with NKRs from iPSCs. We used microarrays to compare mRNA expression profiles of such iPSC-derived mimetic Vγ9Vδ2 T cells with other peripheral blood lymphocytes.

2019-05-31 | GSE126035 | GEO

Proteomics of human Vγ9Vδ2-T cells treated with BSA, PA, or OA by LC-MS/MS

Project description:To better understand the mechanisms underlying the different antitumor activity of Vγ9Vδ2-T cells induced by PA or OA, we performed the proteomic analysis of Vγ9Vδ2-T cells cultured under different conditions.

2025-07-14 | PXD064016 | Pride

An In Vitro Exhaustion Model for Vγ9Vδ2 T Cells: Characterization and Reactivation Strategies for Advancing Immunotherapy Development

Project description:An In Vitro Exhaustion Model for Vγ9Vδ2 T Cells: Characterization and Reactivation Strategies for Advancing Immunotherapy Development

| PRJNA1295886 | ENA

Microbial Product Cocktails for Personalized Cancer Immunotherapy

Project description:<p>The human immune system has evolved to interact with various commensal and pathogenic bacteria in intricate and nuanced ways. While the diversity of bacteria presents fundamental challenges in understanding immune-microbe interactions, it also offers ample opportunities for developing effective immunomodulatory therapies. We introduce microbial product cocktails as a novel class of immunotherapy for cancer. Using freshly resected tumors from bladder cancer patients, an immuno-comparative analysis of recruitment and enhancement assay, and an AI-guided optimization workflow, we established a personalized platform for identifying potent MPCs that promote recruitment, infiltration, and activation of immune cells for cancer treatment. In an orthotopic mouse bladder cancer model, MPCs demonstrated immunoenhancement and improved survival rates compared with standard bacillus Calmette–Guérin immunotherapy.</p>

2025-07-01 | MTBLS12666 | MetaboLights

Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy

Project description:The type of cell death has proven to play a crucial role in cancer immunotherapy efficacy. Immunogenic cell death (ICD) enhances tumor adjuvanticity and antigenicity by releasing danger signals and altering the immune peptidome. The immunogenicity of ferroptosis, an iron-dependent form of cell death, remains uncertain. Proteomic analysis was performed to determine the proteomic changes in the lysate of cells killed by ferroptosis.

2026-03-17 | PXD060116 | Pride

Novel HLA ligands and Tcell epitopes for immunotherapy of lung cancer

Project description:Analysis of gene expression data to evaluate candidate targets for immunotherapy. Analysis of gene expression data to evaluate candidate targets for immunotherapy, We analyse 7 lung cancer samples and 3 reference samples (2x kidney, 1x lung).

2011-07-01 | E-GEOD-27556 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data